Skip to content

Lubiprostone for Long-term Efficacy and Safety in Elderly Patients with Chronic Constipation: An Open-Label, Multicenter Clinical Study

Lubiprostone for Long-term Efficacy and Safety in Elderly Patients with Chronic Constipation: An Open-Label, Multicenter Clinical Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091522
Enrollment
Unknown
Registered
2024-10-30
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation

Interventions

Experimental group:Patients who meet the inclusion criteria will receive 12weeks of lubiprostone treatment, 1 pill per dose,BiD

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: a. Aged 65 or over, with no gender restrictions; b. Meeting the Rome IV diagnostic criteria for functional gastrointestinal disorders; c. Patients have undergone a total colonoscopy within the 2 years prior to the screening period or during the screening period, and the results were clear; d. Signed the informed consent form.

Exclusion criteria

Exclusion criteria: a. Suspected or diagnosed with organic abnormalities in the intestines (obstruction, stenosis, cancer), inflammatory bowel disease, megarectum/megacolon, or pseudo-obstruction; b. Patients with a history of digestive tract or gynecological surgery within the past 3 months; c. Patients with severe cardiovascular system diseases, as judged by the researcher to be unsuitable for participating in the study; d. Abnormal laboratory tests with clinical significance, as judged by the researcher to be unsuitable for participating in the study, including: I. ALT and/or AST > 2 times the upper limit of normal (ULN) II. TBIL >=1.5 times the upper limit value III. Cr higher than the upper limit of normal value; e. Patients with a history of hyperthyroidism or hypothyroidism; f. Other conditions deemed unsuitable for enrollment by the researcher.

Design outcomes

Primary

MeasureTime frame
The frequency of Stool Bowel Movements (SBM) during the 1th week of treatment.;

Secondary

MeasureTime frame
frequencies of SBM;Spontaneous defecation response rate;The time of the first spontaneous defecation;Complete spontaneous defecation frequency;Complete spontaneous defecation response rate;Fecal trait score;Quality of Life Scale for Constipation Patients;Constipation Symptom Self Rating Scale;

Countries

China

Contacts

Public ContactLiu Yulan

Peking University People's Hospital

fanhang1999@sina.com+86 136 4123 4021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026